NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
Moleculin Biotech Inc (NASDAQ: MBRX)
MBRX Technical Analysis
2.5
As on 11th Mar 2025 MBRX STOCK Price closed @ 1.19 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.18 & Strong Buy for SHORT-TERM with Stoploss of 0.51 we also expect STOCK to react on Following IMPORTANT LEVELS. |
MBRXSTOCK Price
Open | 1.12 | Change | Price | % |
High | 1.22 | 1 Day | 0.04 | 3.48 |
Low | 1.10 | 1 Week | -0.10 | -7.75 |
Close | 1.19 | 1 Month | -0.49 | -29.17 |
Volume | 609296 | 1 Year | 0.81 | 213.16 |
52 Week High 5.91 | 52 Week Low 0.38 |
NASDAQ USA Most Active Stocks
SYRS | 0.14 | 55.56% |
AMRS | 0.14 | 100.00% |
BHAT | 0.04 | 33.33% |
NVDA | 108.76 | 1.66% |
CUTR | 0.11 | -15.38% |
AWH | 0.18 | -10.00% |
TSLA | 230.58 | 3.79% |
LMDX | 0.02 | 0.00% |
LCID | 2.09 | 0.48% |
AAL | 11.46 | -8.32% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
MBRX Daily Charts |
MBRX Intraday Charts |
Whats New @ Bazaartrend |
MBRX Free Analysis |
|
MBRX Important Levels Intraday
RESISTANCE | 1.42 |
RESISTANCE | 1.35 |
RESISTANCE | 1.30 |
RESISTANCE | 1.26 |
SUPPORT | 1.12 |
SUPPORT | 1.08 |
SUPPORT | 1.03 |
SUPPORT | 0.96 |
MBRX Forecast March 2025
4th UP Forecast | 1.85 |
3rd UP Forecast | 1.64 |
2nd UP Forecast | 1.51 |
1st UP Forecast | 1.38 |
1st DOWN Forecast | 1 |
2nd DOWN Forecast | 0.87 |
3rd DOWN Forecast | 0.74 |
4th DOWN Forecast | 0.53 |
MBRX Weekly Forecast
4th UP Forecast | 1.31 |
3rd UP Forecast | 1.27 |
2nd UP Forecast | 1.25 |
1st UP Forecast | 1.22 |
1st DOWN Forecast | 1.16 |
2nd DOWN Forecast | 1.13 |
3rd DOWN Forecast | 1.11 |
4th DOWN Forecast | 1.07 |
MBRX Forecast2025
4th UP Forecast | 12.48 |
3rd UP Forecast | 8.86 |
2nd UP Forecast | 6.62 |
1st UP Forecast | 4.38 |
1st DOWN Forecast | -2 |
2nd DOWN Forecast | -4.24 |
3rd DOWN Forecast | -6.48 |
4th DOWN Forecast | -10.1 |
Moleculin Biotech Inc ( NASDAQ USA Symbol : MBRX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
MBRX Other Details
Segment | EQ | |
Market Capital | 76805416.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
MBRX Address
![]() |
MBRX Latest News
MBRX Business Profile
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses in the United States. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and hematologic malignancies. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of topical treatment of cutaneous T-cell lymphoma. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and antimetabolites, targeting glycolysis and glycosylation. The company has partnerships and collaboration agreement with MD Anderson, DERMIN Sp. z o. o., Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o for the development of various drug candidates. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Address: 5300 Memorial Drive, Houston, TX, United States, 77007
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service